Business Context and Reporting Period
Company: Legend Biotech Corporation
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2025
Report Date: August 11, 2025
Business Overview: Legend Biotech is a global biopharmaceutical company focused on cell therapies. Its lead product, CARVYKTI (ciltacabtagene autoleucel), is approved for multiple myeloma and is jointly developed with Janssen Biotech (Johnson & Johnson). The company reported net trade sales of approximately $439 million for CARVYKTI in the period.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2025) | Value (USD Millions) |
|---|---|
| Total Revenue | $450.1 |
| Net Loss | $(226.3) |
| Adjusted Net Income (Loss) | $(16.9) |
| Cash and Cash Equivalents | $266.6 |
| Time Deposits | $701.0 |
| Total Liquidity (Cash + Time Deposits) | $967.6 |
| Net Cash Used in Operating Activities | $(116.8) |
| Collaboration Interest-Bearing Advanced Funding (Debt) | $310.3 (Principal $250.0 + Accrued Interest) |
Note: Revenue is primarily driven by collaboration revenue ($405.3M) from CARVYKTI sales. License revenue was $44.7M.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 60.5% year-over-year (from $280.5M to $450.1M), driven by a 136% increase in collaboration revenue due to higher CARVYKTI sales.
- License Revenue Decline: License revenue decreased 56.6% (from $103.0M to $44.7M). This was primarily due to the absence of a $75.1M milestone payment recognized in the prior year under the Janssen Agreement, partially offset by $20.0M in new related-party license revenue.
- Net Loss Expansion: Net loss widened significantly from $(78.0M) to $(226.3M). This deterioration was largely driven by a $162.6M unrealized foreign exchange loss (compared to a $62.1M gain in the prior year) and increased selling/distribution expenses ($89.0M vs. $54.3M) to support commercial expansion.
- Operating Expenses: Research and development expenses decreased 6.3% to $200.2M as clinical production scaled back at Belgium facilities following commercial launch. Selling and distribution expenses increased 64% to $89.0M.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, time deposits ($1.0B total), and operating cash flows to meet operational and loan repayment needs for at least the next 12 months.
- Profitability Target: The company anticipates achieving operating profit, excluding unrealized foreign exchange gains or losses, in fiscal year 2026.
- Regulatory and Tax Risks: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025, introducing changes to R&D expensing and corporate tax. The impact is currently being evaluated and is not reflected in the June 30, 2025 financials.
- Foreign Exchange Volatility: The company faces significant exposure to USD/EUR exchange rate fluctuations, which caused substantial unrealized losses in the current period. No hedging transactions are currently in place.
- Tariff Exposure: While current pharmaceutical tariffs do not materially impact the company due to domestic U.S. production, future tariffs on imported ingredients could affect costs.
Investor Verification Checklist
- Foreign Exchange Impact: Verify the magnitude of unrealized FX losses ($162.6M) and their impact on reported net loss versus Adjusted Net Income.
- Revenue Sustainability: Confirm the trajectory of CARVYKTI sales growth and the timing of future milestone payments under the Janssen Agreement.
- Liquidity Composition: Review the breakdown of the $1.0B liquidity position, specifically the terms and withdrawal restrictions on the $701M in time deposits.
- Debt Obligations: Assess the terms of the $250M interest-bearing advanced funding from Janssen, including the recoupment mechanism from future collaboration profits.
- Regulatory Changes: Monitor the company's assessment of the OBBBA tax law changes enacted in July 2025.